Clinical Operations

Who Owns the Positive Result? A 2026 Decision Guide for Direct-to-Consumer Cancer Screening

Dr. Sarah Matt, MD, MBA | August 25, 2026 | The Sarah Matt Briefing, Issue 27

The short answer is that nobody has decided, and the default answer is your primary care physicians.

On August 18, 2026, WHOOP announced two things in one press release. It added Galleri, GRAIL's multi-cancer early detection blood test, to its Advanced Labs menu. And it removed the wearable membership requirement, so the test is now buyable by someone who owns a Garmin, an Apple Watch, or nothing at all.

Galleri lists at $799. The draw happens at one of nearly 2,000 Quest locations. GRAIL runs the assay at its North Carolina laboratory. The test is designed to detect cancer signals associated with more than 50 types of cancer, and the result arrives in the WHOOP app.

If you run a primary care network, that last sentence is your operating problem. Not the price, not the science. The delivery path.

What the release says, and what it does not

The WHOOP release is careful and I want to read it just as carefully. "Tests are reviewed and ordered by a licensed healthcare provider." And: "every report is reviewed by a licensed clinician." There is a clinician in the loop. This is not a vending machine, and anyone arguing otherwise has not read the document.

The sentence that should hold your attention is the next one. Results arrive "with educational resources available to help individuals understand their results and determine clinician-directed appropriate next steps."

Read that as an operations person rather than as a lawyer. The ordering clinician's work ends at the report. The next step is a diagnostic workup, and that workup belongs to a clinician who has not been named, has not been paid, and has not agreed to anything.

In practice that clinician is a primary care physician who did not order the test, cannot see how the assay was run, and is now holding a cancer signal with no primary site attached to it.

The four numbers to have in hand before you build the pathway

1. Regulatory status. Galleri has not been cleared or approved by the FDA. It is a laboratory-developed test performed under CLIA at a CAP-accredited laboratory. GRAIL submitted a premarket approval application in January 2026. That application is pending. A pending PMA is not an approval, and your risk committee should hear it stated that plainly.

2. Positive predictive value. In the original PATHFINDER study, PPV was 43 percent. In PATHFINDER 2, it rose to 61.6 percent. Take the better number. Roughly four in ten people who are told they have a cancer signal do not have cancer.

3. Specificity. 99.5 percent in PATHFINDER, 99.6 percent in PATHFINDER 2. That sounds like a rounding error until you multiply the remainder across a large, healthy, self-selected population that is now buying the test on a consumer checkout page.

4. Cancer signal origin accuracy. 88 percent. When the test is right that cancer is present, it points at the correct tissue of origin roughly seven times out of eight. One in eight true positives sends the workup into the wrong organ first.

Both failure modes cost you, and they cost you differently. A false positive means a healthy person gets imaged, sometimes scoped, and carries the word cancer for the six to eight weeks it takes to prove a negative. A misdirected true positive means real disease and a delay while the search starts in the wrong place.

Five decisions to make before the first result walks in

Decision 1: Name the owner. Not a department. A person, with a pager and a backup. The failure mode here is not disagreement, it is silence: primary care assumes oncology, oncology assumes primary care, and the patient calls three times.

Decision 2: Write the pathway down. What imaging, in what order, with what stopping rule. Galleri returns a predicted tissue of origin, so the pathway can be branched rather than a blanket scan-everything protocol. Someone has to build those branches before a patient is sitting in front of you asking what happens next.

Decision 3: Set the stopping rule in advance. This is the decision organizations skip, and it is the one that determines cost. If the directed workup is negative, what happens? Whole-body imaging? Surveillance at three months? Discharge back to routine screening? Decide it when nobody is frightened, because you will not decide it well in the room.

Decision 4: Decide who pays. The test was a consumer purchase. The workup is medical care. Those two facts sit on opposite sides of a coverage line, and your patients do not know that yet. Model the cost of a directed workup for a false positive and know the number before your first prior authorization fight.

Decision 5: Script the negative. A patient who completes a full workup and is told no cancer was found has not been reassured. They have been told the test that scared them was not wrong enough to explain. Somebody has to say something true and useful at that visit, and improvising it is how trust gets spent.

What I would not do

I would not tell patients not to test. That conversation is unwinnable and it is not mine to win. People buying a $799 blood test are engaged with their own health, which is the population you spend the rest of your budget trying to reach.

I would not wait for the PMA decision. The tests are being sold now. Your pathway either exists in September or it gets written in an exam room in October by whoever is on service.

And I would not treat this as a cancer screening problem. It is a demand-routing problem. A consumer company can create clinical demand at a price point and a scale no health system controls, and route the resulting work into your schedule without a referral, a phone call, or a contract. Galleri is the version of that with the highest stakes. It is not going to be the last one.

A consumer company can create clinical demand at a price point and a scale no health system controls, and route the resulting work into your schedule without a referral, a phone call, or a contract.

Where I would start on Monday

Ask one question in your next operations meeting: if a patient walked in tomorrow with a cancer signal detected result and no symptoms, whose name is on the next ninety days?

If the room goes quiet, you have found the gap. Naming the owner takes twenty minutes. Writing the pathway takes a working session. Both are cheaper than the version where a positive result arrives first.

I practice internal medicine. The patient in that scenario is going to be sitting in a room like mine.

Sarah Matt, MD, MBA is a surgery-trained physician-executive currently practicing internal medicine (charity care). She advises health systems and health-tech companies on clinical AI governance and implementation through Vital Werks.

Sources

WHOOP press release, Galleri added to WHOOP Advanced Labs and removal of the membership requirement, August 18, 2026.

GRAIL, Galleri test description, laboratory-developed test performed under CLIA at a CAP-accredited laboratory; premarket approval application submitted January 2026, pending.

PATHFINDER study: positive predictive value 43 percent, specificity 99.5 percent.

PATHFINDER 2 study: positive predictive value 61.6 percent, specificity 99.6 percent, cancer signal origin accuracy 88 percent.

Advisory for Health System Leaders

If nobody in your organization can name the person who owns the ninety days after a consumer cancer screen comes back positive, that pathway is worth writing before the first result arrives. I build it with leadership teams in four to six weeks.

Schedule a scoping call | drsarahmatt.com